Interim Management Statement

FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC                  

      Interim Management Statement - 3 months to 30 June 2008 (unaudited)      

Finsbury Worldwide Pharmaceutical Trust PLC invests in pharmaceutical and
biotechnology companies worldwide with the aim of achieving a high level of
capital growth.

The 3 month period ending 30 June 2008 was a volatile one for the
pharmaceutical sector which saw the Company's undiluted net asset value per
share rise by 2.3% compared to a rise of just 0.2% in the Company's benchmark,
the Datastream World Pharmaceutical and Biotechnology Index measured in
sterling terms on a total return basis.

The Company's share price, however, fell by 2.4% during the three-month period
and a total of 1,516,250 shares were repurchased and held in treasury at a cost
of £7.1m (including expenses).

In the period from 30 June to 31 July, the Company's undiluted net asset value
per share rose by 14.6% and the share price by 11.7% as a result of strong
sectoral performance and in particular from merger and acquisition activity
involving investment portfolio holdings Genentech and Imclone Systems; the
Company's benchmark rose by 5.6% during the same period.

At the Company's Annual General Meeting, held on 23 July 2008, Mr Ian Ivory
retired from the Board. He was succeeded as Chairman by Mr Martin Smith.

On 24 July 2008, all 2,679,750 shares held in treasury were cancelled by the
Company.

The regular exercise date for the Company's warrants is 31 July each year. On
31 July 2008 the Company received notices to exercise 13,070 warrants at an
exercise price of 464p. The remaining opportunity to exercise warrants is on 31
July 2009.

Trust Characteristics

                           30 June 2008               31 Mar 2008              
                                                                               
Number of holdings         36                         39                       
                                                                               
Net assets (£m)            220.4                      222.8                    
                                                                               
Net yield                  0.7%                       0.7%                     
                                                                               
Gearing (AIC basis)        100                        102                      
                                                                               
Share price (p)            446.00                     457.00                   
                                                                               
NAV (p) -undiluted         493.40                     482.34                   
                                                                               
NAV (p) diluted: warrants  487.69                     478.88                   
                                                                               
NAV (p) - fully diluted    485.96                     478.54                   
for                                                                            
                                                                               
warrants and treasury                                                          
shares                                                                         
                                                                               
(Discount)/premium         (9.6%)                     (5.3%)                   
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted  (8.5%)                     (4.6%)                   
- warrants)                                                                    
                                                                               
(Discount/premium (fully   (8.2%)                     (4.5%)                   
diluted)                                                                       
                                                                               
Warrant price (p)          31.50                      27.50                    

Source: Frostrow Capital LLP

10 Largest Investments

Name                                  % of                       % of           
                                                                                
                              investment portfolio       investment portfolio   
                                                                                
                                at 30 June 2008             at 31 Mar 2008      
                                                                                
Novartis                              6.2                         5.6                       
                                                                                
Genzyme                               5.7                         5.7                       
                                                                                
Genentech                             5.6                         5.8                       
                                                                                
Abbott Laboratories                   5.3                         5.3                       
                                                                                
Bristol-Myers Squibb                  5.1                         5.1                       
                                                                                
Schering-Plough                       5.1                         3.6                       
                                                                                
Imclone Systems                       4.8                         2.6                       
                                                                                
Roche                                 4.5                         4.4                       
                                                                                
Onyx Pharmaceuticals                  3.9                         2.6                       
                                                                                
Biogen Idec                           3.9                         4.2                       
                                                                                
Total                                50.1                        44.9                      

Source: Frostrow Capital LLP

Sector Analysis

                                      % of                       % of           
                                                                                
                              investment portfolio       investment portfolio   
                                                                                
                                at 30 June 2008             at 31 Mar 2008      
                                                                                
Large capitalisation                  54.0                       56.9           
                                                                                
Small capitalisation                  46.0                       43.1           
                                                                                
Total                                100.0                      100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                             investment portfolio       investment portfolio   
                                                                               
                               at 30 June 2008             at 31 Mar 2008      
                                                                               
North America                        80.4                       75.2           
                                                                               
Europe                               12.6                       15.9           
                                                                               
Japan                                7.0                        8.9            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     -2.4%           -7.6%           -3.1%           +6.3%          
                                                                               
NAV Fully       +1.6%           -5.9%           +6.1%           +8.7%          
diluted                                                                        
                                                                               
Benchmark*      0.2%            -6.1%           +3.5%           +11.2%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Fundamental Data. Benchmark - Thomson Reuters.

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.finsburywp.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

11 August 2008